Neurocrine Biosciences (NASDAQ:NBIX) has been under a strong bear grip, hence the stock is down -1.18% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 5.91% in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 7.26% in the last 1 week, and is up 0.41% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The company shares have dropped -3.78% from its 1 Year high price. On Nov 27, 2015, the shares registered one year high at $58.46 and the one year low was seen on Feb 9, 2016. The 50-Day Moving Average price is $46.94 and the 200 Day Moving Average price is recorded at $43.65.
The stock has recorded a 20-day Moving Average of 6.83% and the 50-Day Moving Average is 5.3%.
Neurocrine Biosciences (NASDAQ:NBIX): stock turned positive on Friday. Though the stock opened at $47.92, the bulls momentum made the stock top out at $48.82 level for the day. The stock recorded a low of $47.06 and closed the trading day at $48.58, in the green by 1.10%. The total traded volume for the day was 862,086. The stock had closed at $48.05 in the previous days trading.
In an insider trading activity, Lloyd-Smith Malcolm, officer (Chief Regulatory Officer) of Neurocrine Biosciences Inc, unloaded 9,000 shares at an average price of $50 on May 31, 2016. The total amount of the transaction was worth $450,000, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Neurocrine Biosciences, Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine based diseases and disorders. The Companys two lead late-stage clinical programs are elagolix, a gonadotropin releasing hormone (GnRH) antagonist for womens health that is partnered with AbbVie Inc. (AbbVie), and a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. elagolix is in clinical trials for the treatment of Endometriosis and Uterine Fibroids. VMAT2 (NBI-98854) is a VMAT2 inhibitor in clinical trials for the treatment of tardive dyskinesia. Corticotropin-Releasing Factor (CRF) receptor antagonist (NBI-77860) is indicated for the treatment of Classic Congenital Adrenal Hyperplasia. NBI-77860 is a selective, orally-active, non-peptide CRF receptor antagonist.